THERAPY DOSSIER · th-bb87de9b029d

Flagellin (TLR5 agonist) or lipopolysaccharide (TLR4 agonist)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00966238 ↗PHASE2completed

VAX125 (flagellin-based) influenza vaccine in community-living adults 65 years and over

Influenza

Enrolment: 120 · Results not recorded

NCT00921947 ↗PHASE1/PHASE2completed

VAX102 (M2e-flagellin) intramuscular versus subcutaneous dosing in healthy adults

Influenza

Enrolment: 60 · Results not recorded

NCT01527136 ↗PHASE1completed

Phase 1 safety and pharmacokinetics of CBLB502 (entolimod, flagellin derivative) in advanced cancers

Adult solid tumour

Enrolment: 25 · Results not recorded

NCT03063736 ↗EARLY_PHASE1completed

Entolimod, an adjuvant for vaccine augmentation

Substance use disorders

Enrolment: 40 · Results not recorded

NCT01381744 ↗PHASE1completed

Plague vaccine flagellin/F1/V, phase 1 dose escalation in healthy adults

Plague

Enrolment: 48 · Results not recorded

NCT00603811 ↗PHASE1completed

VAX102 (flagellin.HuM2e) influenza vaccine, dose-ranging safety and immunogenicity

Influenza infection

Enrolment: 60 · Results not recorded

NCT06768697 ↗EARLY_PHASE1not yet recruiting

Recombinant flagellin protein adjuvant in a SARS-CoV-2 subunit mucosal vaccine (KFD1)

COVID-19

Enrolment: 60 · Results not recorded

NCT00124865 ↗PHASE1withdrawn

Intranasal recombinant flagellin subunit Campylobacter vaccine (rFla-MBP)

Diarrhoea

Enrolment: 0 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23596059 ↗2013Reported benefit

Flagellin or lipopolysaccharide treatment modified macrophage populations after colorectal radiation of rats.

RatRadiationSprague-DawleyMaleIntraperitoneal50 or 200 micrograms per ratThree days after irradiation

Model: Single 20 or 27 Gy dose of colorectal irradiation

Irradiation increased TLR4+ and TLR5+ macrophage frequency, and flagellin or lipopolysaccharide maintained this elevation after 27 Gy while shifting macrophages towards an M2 phenotype, correlating with epithelial regeneration.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…